GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (XMAD:GRF) » Definitions » E10

Grifols (XMAD:GRF) E10 : €0.83 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Grifols E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Grifols's adjusted earnings per share data for the three months ended in Dec. 2023 was €0.082. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.83 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Grifols's average E10 Growth Rate was 2.50% per year. During the past 3 years, the average E10 Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Grifols was 17.40% per year. The lowest was 5.30% per year. And the median was 11.35% per year.

As of today (2024-04-27), Grifols's current stock price is €8.386. Grifols's E10 for the quarter that ended in Dec. 2023 was €0.83. Grifols's Shiller PE Ratio of today is 10.10.

During the past 13 years, the highest Shiller PE Ratio of Grifols was 96.30. The lowest was 9.07. And the median was 26.71.


Grifols E10 Historical Data

The historical data trend for Grifols's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols E10 Chart

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.71 0.77 0.81 0.83

Grifols Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.81 0.83 0.84 0.83

Competitive Comparison of Grifols's E10

For the Drug Manufacturers - General subindustry, Grifols's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Grifols's Shiller PE Ratio falls into.



Grifols E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Grifols's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.082/121.2698*121.2698
=0.082

Current CPI (Dec. 2023) = 121.2698.

Grifols Quarterly Data

per share eps CPI Adj_EPS
201306 0.135 100.994 0.162
201309 0.125 100.597 0.151
201312 0.115 101.306 0.138
201403 0.175 100.139 0.212
201406 0.150 101.081 0.180
201409 0.165 100.441 0.199
201412 0.195 100.251 0.236
201503 0.190 99.474 0.232
201506 0.190 101.138 0.228
201509 0.200 99.559 0.244
201512 0.190 100.268 0.230
201603 0.180 98.638 0.221
201606 0.200 100.333 0.242
201609 0.210 99.737 0.255
201612 0.204 101.842 0.243
201703 0.196 100.896 0.236
201706 0.210 101.848 0.250
201709 0.220 101.524 0.263
201712 0.338 102.975 0.398
201803 0.210 102.122 0.249
201806 0.260 104.165 0.303
201809 0.220 103.818 0.257
201812 0.180 104.193 0.210
201903 0.170 103.488 0.199
201906 0.250 104.612 0.290
201909 0.200 103.905 0.233
201912 0.290 105.015 0.335
202003 0.272 103.469 0.319
202006 0.050 104.254 0.058
202009 0.390 103.521 0.457
202012 0.190 104.456 0.221
202103 0.190 104.857 0.220
202106 0.200 107.102 0.226
202112 -0.110 111.298 -0.120
202206 0.133 118.044 0.137
202209 0.066 117.221 0.068
202212 0.030 117.650 0.031
202306 0.088 120.278 0.089
202309 0.088 121.343 0.088
202312 0.082 121.270 0.082

Add all the adjusted EPS together and divide 10 will get our e10.


Grifols  (XMAD:GRF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Grifols's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=8.386/0.83
=10.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Grifols was 96.30. The lowest was 9.07. And the median was 26.71.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Grifols E10 Related Terms

Thank you for viewing the detailed overview of Grifols's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols (XMAD:GRF) Business Description

Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.